Biosensors International Group today announced the acquisition of certain assets of Devax, Inc., a maker of specialty stents, for a total consideration of US$5.7 million ($7.4 million).
Headquartered in Irvine, California, US, Devax develops the Axxess drug-eluting stent (DES) system designed specifically to treat the complex type of coronary artery disease that forms at the intersection of two vessels. Coronary bifurcations are prone to develop atherosclerotic plaque because of turbulent blood flow and high shear stress near the main branch and the adjacent side branch.



